1190615-03-2

Basic information

• Product Name: 5-{(R)-{[tert-butyl(dimethyl)silyl]oxy}[(2R)-5-(4-nitrobenzyl)-3,4-dihydro-2H-pyrrol-2-yl]methyl}-2-chloropyridine
• Synonyms: 5-{(R)-{[tert-butyl(dimethyl)silyl]oxy}[(2R)-5-(4-nitrobenzyl)-3,4-dihydro-2H-pyrrol-2-yl]methyl}-2-chloropyridine
• CAS NO: 1190615-03-2
• Molecular Weight: 460.048
• Mol File: 1190615-03-2.mol

Chemical Properties

• CAS DataBase Reference: 5-{(R)-{[tert-butyl(dimethyl)silyl]oxy}[(2R)-5-(4-nitrobenzyl)-3,4-dihydro-2H-pyrrol-2-yl]methyl}-2-chloropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-{(R)-{[tert-butyl(dimethyl)silyl]oxy}[(2R)-5-(4-nitrobenzyl)-3,4-dihydro-2H-pyrrol-2-yl]methyl}-2-chloropyridine(1190615-03-2)
• EPA Substance Registry System: 5-{(R)-{[tert-butyl(dimethyl)silyl]oxy}[(2R)-5-(4-nitrobenzyl)-3,4-dihydro-2H-pyrrol-2-yl]methyl}-2-chloropyridine(1190615-03-2)

Safety Data

• Hazardous Substances Data: 1190615-03-2(Hazardous Substances Data)

Upstream product

• 1190614-96-0 (S)-4-benzyl-3-((R)-2-((S)-(6-chloropyridin-3-yl)(hydroxy)methyl)hex-5-ynoyl)oxazolidin-2-one 
• 1190614-97-1 (S)-4-benzyl-3-((R)-2-((S)-(6-chloropyridin-3-yl)((trimethylsilyl)oxy)methyl)hex-5-ynoyl)oxazolidin-2-one 
• 1190614-98-2 (R)-2-((S)-(6-chloropyridin-3-yl)((trimethylsilyl)oxy)methyl)hex-5-ynoic acid 
• 1190614-94-8 4-methoxybenzyl ((1R,2R)-1-((tert-butyldimethylsilyl)oxy)-1-(6-chloropyridin-3-yl)hex-5-yn-2-yl)carbamate 
• 1190615-01-0 4-methoxybenzyl ((1R,2R)-1-((tert-butyldimethylsilyl)oxy)-1-(6-chloropyridin-3-yl)-6-(4-nitrophenyl)hex-5-yn-2-yl)carbamate 
• 23100-12-1 6-chloronicotinylaldehyde 

Downstream Products

• 1190615-05-4 (2S,5S)-tert-butyl 2-((R)-((tert-butyldimethylsilyl)oxy)(6-chloropyridin-3-yl)methyl)-5-(4-nitrobenzyl)pyrrolidine-1-carboxylate 
• 1190615-04-3 (2S,5R)-tert-butyl-2-(4-aminobenzyl)-5-((R)-((tert-butyldimethylsilyl) oxy)(pyridin-3-yl)methyl)pyrrolidine-1-carboxylate 
• 1190615-16-7 (2S,5R)-tert-butyl 2-(4-aminobenzyl)-5-((R)-hydroxy(pyridin-3-yl)methyl)pyrrolidine-1-carboxylate 
• 1190615-22-5 tert-butyl (2S,5R)-2-(4-amino-3-bromobenzyl)-5-[(R)-hydroxy(pyridin-3-yl)methyl]pyrrolidine-1-carboxylate 
• 1190615-33-8 tert-butyl (2S,5R)-2-(4-{[(2S)-2-aminopropanoyl]amino}benzyl)-5-[(R)-hydroxy(pyridin-3-yl)methyl]pyrrolidine-1-carboxylate 
• 1190615-06-5 tert-butyl (2R,5R)-2-(4-aminobenzyl)-5-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(pyridine-3-yl)methyl]pyrrolidine-1-carboxylate 
• 1190615-35-0 tert-butyl (2R,5S)-2-[(R)hydroxy(pyridin-3-yl)methyl]-5-(4-{[(2S)-2-(methylamino)propanoyl]amino}benzyl)pyrrolidine-1-carboxylate 
• 1190615-07-6 tert-butyl (2R,5R)-2-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(6-chloropyridin-3-yl)methyl]-5-(4-nitrobenzyl)pyrrolidine-1-carboxylate 
• 1190615-44-1 tert-butyl (2R,5S)-2-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(pyridin-3-yl)methyl]-5-(4-{[(2R)-2-pyridin-2-ylpropanoyl]amino}benzyl)pyrrolidine-1-carboxylate 
• 1190615-45-2 tert-butyl (2R,5S)-2-[(R)-{[tert-butyl(dimethyl)silyl]oxy}(pyridin-3-yl)methyl]-5-(4-{[(2S)-2-pyridin-2-ylpropanoyl]amino}benzyl)pyrrolidine-1-carboxylate 
• 1190611-29-0 (2S)-N-[4-({(2S,5R)-5-[(R)-hydroxy(pyridin-3-yl)methyl]pyrrolidin-2-yl}methyl)phenyl]-2-pyridin-2-ylpropanamide trifluoroacetate 
• 1190609-33-6 N-[4-({(2S,5R)-5-[(R)-hydroxy(pyridin-3-yl)methyl]pyrrolidin-2-yl}methyl)phenyl]-2-(2-oxopyrrolidin-1-yl)acetamide trifluoroacetamide 
• 1190609-31-4 2-(2-amino-1,3-thiazol-4-yl)-N-[4-({(2S,5R)-5-[(R)-hydroxy(pyridin-3-yl)methyl]pyrrolidin-2-yl}methyl)phenyl]acetamide trifluoroacetate 
• 1190615-41-8 tert-butyl (2R,5S)-2-[(R)-hydroxy(pyridin-3-yl)methyl]-5-(4-{[(2-oxopyrrolidin-1-yl)acetyl]amino}benzyl)pyrrolidine-1-carboxylate trifluoroacetate 

Relevant articles and documents

NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of b3-adrenoceptor.

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.